sinc
milstein
first
report
develop
hybridoma
technolog
revolut
taken
place
research
clinic
medicin
area
infecti
diseas
monoclon
antibodi
use
power
probe
defin
antigen
structur
virul
mechan
host
respons
broad
rang
pathogen
includ
bacteria
virus
parasit
numer
advanc
immunodiagnosi
prophylaxi
therapi
result
futur
applic
forthcom
everacceler
rate
gener
introduct
hybridoma
technolog
potenti
applic
monoclon
antibodi
veterinari
medicin
first
appear
veterinari
literatur
often
case
new
knowledg
lead
increas
special
evidenc
present
volum
focus
monoclon
antibodi
sole
bacteria
particular
chapter
special
deal
specif
discuss
current
futur
applic
monoclon
antibodi
bacteria
clinic
veterinari
medicin
research
clinician
veterinari
medicin
cogniz
tremend
impact
monoclon
antibodi
area
research
clinic
applic
human
medicin
report
research
involv
monoclon
antibodi
begun
appear
veterinari
literatur
rel
littl
research
activ
howev
direct
toward
studi
bacteria
cumul
index
veterinariu
entri
monoclon
antibodi
edit
entri
dealt
viral
antigen
identifict
eukaryot
cell
surfac
marker
three
paper
dealt
specif
bacteri
antigen
edit
monoclon
antibodi
citat
involv
bacteria
entri
dealt
specif
bacteria
view
scarciti
publish
materi
emphasi
chapter
current
futur
applic
monoclon
antibodi
veterinari
medicin
necess
deal
larg
futur
use
understand
control
infecti
diseas
continu
major
challeng
veterinari
medicin
bacteri
pathogen
still
major
concern
million
research
fund
avail
veterinari
research
unit
state
depart
agricultur
scienc
educ
administr
competit
basi
studi
anim
diseas
sixtysix
percent
fund
award
research
studi
infecti
diseas
problem
portion
went
specif
studi
bacteri
diseas
reason
assum
increas
number
bacteri
diseas
investig
includ
use
monoclon
antibodi
futur
four
major
use
monoclon
antibodi
bacteria
veterinari
medicin
readili
identifi
character
bacteri
antigen
virul
factor
elucid
pathogenesi
bacteri
infect
improv
immunodiagnosi
clinic
applic
treatment
prophylaxi
focu
present
primarili
diagnost
clinic
applic
acknowledg
outset
advanc
area
depend
critic
advanc
basic
research
structur
function
bacteri
pathogen
recent
develop
monoclon
antibodi
pilu
enteropathogen
e
coli
passiv
immun
calv
enter
colibacillosi
possibl
develop
hybridoma
technolog
preced
year
basic
research
numer
worker
identif
adher
factor
enter
bacteria
role
pathogenesi
diarrhea
antigen
structur
virul
attribut
pathogen
mechan
mani
import
bacteri
pathogen
veterinari
medicin
still
uncharacter
hybridoma
technolog
readili
avail
research
tool
monoclon
antibodi
undoubtedli
aid
first
defin
unknown
provid
new
diagnost
clinic
applic
certain
limit
practic
veterinari
medicin
make
potenti
diagnost
clinic
use
monoclon
antibodi
attract
food
anim
practition
must
often
carri
thorough
clinic
examin
diagnost
workup
isol
barn
feedlot
arriv
specif
diagnosi
institut
therapeut
plan
singl
farm
visit
entir
herd
flock
threaten
spread
rapidli
dissemin
infecti
diseas
process
take
urgenc
accuraci
diagnosi
becom
extrem
import
submiss
sampl
distant
diagnost
laboratori
impract
develop
rapid
reliabl
immunodiagnost
test
kit
use
farm
recogn
need
certain
immunodiagnost
procedur
enzymelink
immunosorb
assay
elisa
adapt
onfarm
inpractic
use
inclus
monoclon
antibodi
reagent
kit
greatli
enhanc
practic
specif
monoclon
antibodi
would
allow
diagnost
test
perform
directli
crude
specimen
fece
pu
mastit
milk
lavag
fluid
without
intermedi
step
bacteri
cultur
furthermor
monospecif
reagent
virtual
elimin
problem
crossreact
occur
convent
deriv
polyclon
reagent
specif
diseas
diagnost
capabl
would
advantag
practition
discuss
clinic
applic
tremend
potenti
veterinari
medicin
diseas
prevent
passiv
immun
particularli
newli
initi
infect
threaten
spread
rapidli
suscept
herd
flock
mani
situat
numer
extrins
factor
play
role
initi
spread
oi
bacteri
diseas
factor
includ
weather
condit
concurr
vira
infect
sanit
nutrit
statu
stress
factor
stock
rate
ventila
tion
recent
transport
diseas
outbreak
often
explos
unpr
dictabl
mani
case
activ
immun
vaccin
taken
diseas
outbreak
unexpect
efficaci
vaccin
avail
costbenefit
ratio
prophylaxi
consid
situa
tion
practition
current
must
interven
antibioti
therapi
effort
reduc
morbid
mortal
howev
use
antibiot
therapi
foodproduc
anim
come
increas
scrutini
due
concern
transfer
drug
resist
anim
human
pathogen
intervent
parenter
administr
monoclon
antibodi
direct
specif
virul
factor
pathogen
involv
order
reduc
morbid
offer
attract
altern
antibiot
therapi
knowledg
virul
factor
bacteri
pathogen
increas
diseas
outbreak
undoubtedli
handl
way
specif
diseas
entiti
approach
current
employ
well
diseas
intervent
like
success
discuss
detail
practic
applic
monoclon
antibodi
clinic
veterinari
medicin
must
preced
firm
basic
knowledg
structur
charact
virul
factor
pathogen
mechan
diseaseproduc
bacteria
structur
chapter
base
structur
bacteria
becom
readili
appar
known
role
particular
structur
compon
causat
diseas
firmli
base
specul
applic
monoclon
antibodi
bacteri
compon
limit
space
prohibit
extens
discuss
diseas
condit
present
chapter
although
attempt
made
provid
suffici
background
materi
diseas
reader
familiar
clinic
veterinari
medicin
refer
standard
textbook
veterinari
medicin
clarif
pili
proteinac
filament
appendag
cell
surfac
certain
bacteria
fig
also
known
fimbria
adhesin
adher
factor
colon
factor
role
pili
enabl
certain
pathogen
colon
epitheli
surfac
success
well
establish
human
medicin
pili
recogn
virul
factor
infect
neisseria
gonorrhoea
enteropathogen
escherichia
coli
epec
pseudomona
aeruginosa
among
other
veterinari
medicin
import
pilusmedi
adher
also
identifi
epec
infect
caus
neonat
enter
colibacillosi
calv
lamb
pig
moraxella
bovi
infect
caus
infecti
bovin
keratoconjunct
ibk
pinkey
bacteroid
nodosu
infect
caus
foot
rot
sheep
role
pilusmedi
adher
investig
number
import
veterinari
pathogen
includ
variou
salmonella
pasteurella
bordetella
speci
knowledg
led
develop
pilusenrich
vaccin
activ
immun
pathogen
case
enteropathogen
e
coli
monoclon
antibodi
develop
diagnost
use
well
passiv
immun
newborn
calv
pig
develop
well
potenti
applic
monoclon
antibodi
control
pinkey
foot
rot
pilusmedi
infect
veterinari
medicin
discuss
pilu
passiv
immun
develop
monoclon
antibodi
pilu
epec
passiv
protect
newborn
calv
fatal
enter
colibacillosi
illustr
firm
knowledg
pathogenesi
epidemiolog
specif
diseas
lead
innov
method
diseas
control
strain
noninvas
e
coli
capabl
produc
diarrhea
noenat
must
possess
two
virul
factor
plasmid
mediat
first
must
enterotoxigen
possess
either
heatstabl
heatlabil
enterotoxin
capabl
induc
villou
epitheli
cell
second
must
possess
pili
colon
gut
success
adher
villou
epithelium
physic
proxim
bacteria
villou
surfac
facilit
pilu
adher
maxim
deleteri
effect
enterotoxin
nonpili
enterotoxigen
strain
piliat
nonenterotoxigen
strain
produc
diseas
equal
magnitud
enteropathogen
strain
possess
pilu
toxin
pilu
found
epec
infect
calv
lamb
pig
first
report
identifi
time
kco
common
k
antigen
design
isol
pilu
accomplish
either
salt
extract
procedur
ultrason
mechan
heat
shake
cell
suspens
earli
report
structur
pilu
suggest
compos
two
protein
subunit
major
compon
mw
minor
subunit
mw
recent
work
indic
pilu
compos
singl
subunit
mw
electron
microscop
examin
reveal
fimbria
helic
configur
diamet
nm
purifi
pili
strongli
immunogen
suscept
calv
lamb
colon
epec
age
depend
speci
becom
resist
experiment
challeng
day
age
demonstr
vivo
vitro
although
natur
natur
resist
well
understood
clinic
signific
observ
profound
led
hypothesi
suscept
enter
colibacillosi
occur
first
day
life
presenc
antibodi
gut
lumen
time
might
success
block
intestin
adher
epec
thu
inhibit
colon
time
calf
possess
natur
resist
infect
livestock
speci
matern
antibodi
deriv
colostr
ingest
rather
transplacent
transfer
experi
undertaken
demonstr
whether
cow
vaccin
prepartum
kill
bacterin
contain
either
strain
e
coli
purifi
pili
would
produc
concentr
antibodi
colostrum
calv
ingest
colostrum
birth
would
protect
enter
colibacillosi
hypothesi
proven
repeatedli
accur
experiment
challeng
studi
result
numer
vaccin
becom
commerci
avail
activ
immun
cow
passiv
protect
calf
histori
vaccin
develop
enter
colibacillosi
calv
recent
review
although
vaccin
use
appar
success
practic
disadvantag
matern
vaccin
recogn
pregnant
cow
must
handl
vaccin
twice
first
year
subsequ
year
vaccin
program
livestock
owner
reluct
accept
cost
inconveni
prevent
vaccin
unless
recent
experienc
outbreak
enter
colibacillosi
herd
outbreak
difficult
predict
sinc
epizootiolog
neonat
calf
diarrhea
includ
varieti
manag
environment
factor
outbreak
occur
suddenli
unvaccin
herd
late
immun
activ
pregnant
cow
close
parturit
concern
prompt
investig
altern
method
passiv
immun
newborn
calv
name
oral
administr
hybridomaderiv
monoclon
antibodi
shortli
birth
develop
monoclon
antibodi
effacaci
protect
calv
fatal
enter
colibacillosi
challeng
trial
report
repres
first
known
applic
monoclon
antibodi
passiv
immun
import
bacteri
diseas
detail
work
briefli
review
sourc
antigen
pilu
strain
epec
isol
purifi
accord
method
isaacson
antigen
complet
freund
adjuv
inject
balbc
mice
spleen
remov
seri
three
antigen
inject
hybridoma
produc
polyethylen
glycolmedi
fusion
mous
spleen
cell
mous
plasmacytoma
cell
line
result
hybridoma
grown
select
medium
contain
hypoxanthin
aminopterin
thymidin
tissu
cultur
plate
supernat
well
hybridoma
clone
screen
antibodi
use
eli
techniqu
purifi
antigen
hybridoma
monoclon
produc
monoclon
antibodi
isol
limit
dilut
singl
clone
select
inject
intraperiton
specif
pathogenfre
balbc
mice
precondit
pristan
mice
kill
day
later
ascit
fluid
aspir
fluid
clarifi
centrifug
store
character
monoclon
antibodi
accomplish
use
sever
techniqu
includ
eli
bacteri
agglutin
immunoprecipit
radiolabel
epec
strain
monoclon
antibodi
clone
shown
igg
eli
rabbit
antimous
lgg
l
antibodi
pool
ascit
fluid
clone
exhibit
titer
system
immunoglobulin
constitut
protein
ascit
fluid
determin
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
fig
antibodi
found
reactiv
antigen
radioimmunoprecipit
l
methioninelabel
e
coli
lysat
follow
sdspage
immunoglobulin
initi
concentr
mgml
agglutin
epec
strain
grown
fig
immunoprecipit
l
methioninelabel
lysat
epec
strain
monoclon
antibodi
oral
administ
calv
immunoprecipit
subject
electrophoresi
acrylamid
slab
gel
protein
lane
detect
coomassi
blue
stain
prior
salicyl
gel
molecular
weight
marker
thousand
k
indic
lane
antigen
use
subsequ
product
monoclon
antibodi
indic
arrow
lane
lane
repres
radioact
antigen
precipit
epec
strain
monoclon
antibodi
lane
repres
similar
precipit
fibronectinspecif
monoclon
antibodi
reprint
refer
permiss
american
societi
microbiolog
copyright
infect
immun
pilu
express
dilut
agglutin
cell
grown
pilu
express
even
use
three
separ
challeng
trial
conduct
evalu
efficaci
oral
administ
monoclon
antibodi
protect
neonat
calv
enter
colibacillosi
first
trial
newborn
calv
fed
colostrum
birth
challeng
oral
x
organ
epec
strain
h
hr
age
hour
age
treat
calv
receiv
ml
clarifi
mous
ascit
fluid
contain
monoclon
antibodi
titer
determin
passiv
hemagglutin
control
calv
receiv
placebo
second
third
trial
newborn
calv
colostrum
depriv
birth
calv
challeng
averag
x
organ
epec
strain
hr
age
treat
calv
receiv
oral
dose
mous
ascit
fluid
hr
age
control
calv
receiv
placebo
ml
mous
ascit
fluid
contain
monoclon
antibodi
specif
fibronectin
differ
trial
trial
calv
receiv
treatment
known
investig
trial
perform
doubl
blind
trial
calv
examin
everi
hr
clinic
statu
score
base
assess
state
dehydr
fecal
consist
mental
attitud
hr
postchalleng
treatment
monoclon
antibodi
affect
incid
diarrhea
challeng
epec
strain
differ
proport
treat
control
calv
develop
diarrhea
three
trial
tabl
signific
differ
averag
score
fecal
consist
treat
control
group
three
trial
tabl
ii
calcul
trial
also
signific
differ
time
onset
diarrhea
challeng
control
treat
calv
contrast
result
signific
differ
incid
sever
dehydr
measur
estim
loss
skin
elast
control
treat
calv
tabl
proport
calv
becam
sever
dehydr
challeng
significantli
lower
calv
receiv
monoclon
antibodi
compar
control
calv
three
trial
reduct
highli
signific
p
result
three
trial
combin
also
signific
reduct
sever
system
ill
treatment
control
group
three
trial
measur
comparison
mean
score
earn
degre
clinic
dehydr
degre
clinic
depress
maximum
clinic
score
tabl
ii
addit
signific
differ
note
durat
diarrhea
challeng
measur
trial
signific
differ
observ
degre
weight
loss
treat
control
calv
measur
trial
tabl
ii
importantli
treatment
monoclon
antibodi
significantli
reduc
mortal
challeng
calv
three
trial
tabl
result
three
trial
consid
togeth
mortal
rate
calv
receiv
monoclon
antibodi
compar
control
calv
differ
highli
signific
p
conclud
treatment
ml
mous
ascit
fluid
contain
monoclon
antibodi
reduc
sever
diarrhea
mortal
rate
challeng
epec
strain
find
support
earlier
work
indic
immun
cow
purifi
antigen
calv
stimul
product
antibodi
passiv
transfer
calv
prevent
fatal
diarrhea
studi
antibodi
direct
pilu
epec
significantli
reduc
sever
diarrhea
caus
strain
carri
two
adher
pili
well
capsular
antigen
also
believ
mediat
adher
suggest
degre
colon
henc
clinic
sever
diseas
reduc
monoclon
antibodi
fact
diarrhea
elimin
complet
attribut
possibl
either
perform
enterotoxin
present
challeng
inoculum
dose
monoclon
antibodi
suffici
block
adher
pili
complet
adher
colon
gut
may
occur
fact
treat
calv
die
attribut
sever
factor
includ
depriv
colostrum
trial
presenc
concurr
infect
postmortem
examin
treat
calv
reveal
presenc
concurr
rotaviru
andor
coronaviru
intestin
work
led
develop
use
commerci
avail
monoclon
antibodi
prepar
oral
administr
newborn
calv
prevent
fatal
enter
colibacillosi
applic
hybridoma
technolog
develop
antibodi
could
prepar
convent
mean
perceiv
case
technolog
overkil
fact
convent
rais
antibodi
product
oral
administr
directli
calv
develop
market
israel
howev
hybridoma
technolog
advanc
dramat
sinc
first
publish
report
cost
produc
hybridomaderiv
monoclon
antibodi
compar
favor
product
convent
antisera
c
c
muscoplat
molecular
genet
inc
minnetonka
minnesota
person
commun
superior
convent
produc
antisera
obviou
specif
concentr
uniform
hybridomaderiv
antibodi
consid
immunodiagnosi
develop
monoclon
antibodi
pilu
consider
impact
diagnosi
enter
colibacillosi
rapid
diagnosi
enteropathogen
e
coli
caus
neonat
diarrhea
import
sever
reason
diseas
tend
spread
rapidli
among
newborn
calv
particularli
cattl
maintain
close
quarter
numer
etiolog
agent
may
produc
diarrhea
young
calv
although
epec
account
major
infect
rotaviru
coronaviru
salmonella
sp
clostridium
perfringen
cryptosporidia
less
common
pathogen
may
also
occur
specif
diagnosi
epec
allow
practition
choos
appropri
therapi
initi
prevent
program
offer
accur
prognosi
convent
diagnost
procedur
collect
fecal
swab
live
calf
ileal
swab
necropsi
subsequ
cultur
medium
favor
pilu
express
mincai
overnight
incub
sever
coloni
select
slide
agglutin
test
perform
use
convent
rais
antisera
altern
coloni
smear
slide
examin
use
fluorescentantibodi
techniqu
antisera
conjug
fluorescein
sever
limit
exist
method
techniqu
overnight
cultur
requir
isol
epec
diagnosi
made
practition
may
equip
perform
either
test
sinc
mani
nonpathogen
e
coli
may
present
fecal
swab
inappropri
select
coloni
initi
cultur
may
lead
falseneg
result
ellen
et
al
report
develop
eli
techniqu
allow
detect
antigen
directli
calf
fece
comparison
convent
cultur
agglutin
techniqu
diagnost
sensit
eli
equival
standard
test
howev
overnight
cultur
elimin
test
result
avail
hr
elisa
employ
rabbitderiv
antisera
purifi
adsorpt
hyperimmun
serum
variant
parent
strain
pilu
first
deriv
perform
elisa
extens
process
fecal
specimen
first
requir
sampl
dilut
phosphatebuff
salin
homogen
ultrason
centrifug
clarif
crossreact
occur
bovin
coronaviru
present
fecal
specimen
requir
block
bovin
anticoronaviru
serum
mill
techniqu
requir
prepar
fecal
sampl
yield
result
less
hour
design
test
kit
use
veterinari
practic
sourc
monoclon
antibodi
clone
fecal
swab
sampl
fece
suspend
ina
tube
diluent
buffer
shake
monoclon
antibodi
link
horseradish
peroxidas
ad
tube
polystyren
wand
coat
monoclon
antibodi
place
sampl
tube
incub
min
wand
wash
cold
water
place
second
tube
contain
enzym
substrat
min
color
chang
visual
observ
posit
control
run
sampl
color
standard
result
base
concentr
pilu
antigen
sampl
read
neg
antigen
low
posit
high
posit
antigen
due
consist
concentr
avid
monoclon
reagent
sensit
test
easili
titrat
desir
level
sensit
specif
test
system
demonstr
test
fecal
sampl
gnotobiot
calv
infect
variou
enter
virus
well
test
bacteri
cultur
numer
speci
strain
enter
bacteria
known
neg
two
variat
test
system
use
monoclon
antibodi
reagent
report
competit
elisa
test
threestep
sandwich
elisa
system
latter
sinc
market
commerci
practic
veterinarian
b
pilu
pilu
found
epec
isol
porcin
enter
colibacillosi
presenc
pilu
plasmid
mediat
appear
strong
associ
certain
serotyp
epec
notabl
strain
carri
pilu
may
produc
either
heatstabl
heatlabil
enterotoxin
pili
strain
visibl
electron
microscopi
diamet
nm
molecular
weight
rang
three
immunolog
distinct
pilu
structur
recogn
fraction
repres
common
antigen
determin
partial
amino
acid
sequenc
three
antigen
character
plasmid
gene
respons
product
isol
molecular
clone
progress
understand
role
adhesin
porcin
enter
colibacillosi
develop
vaccin
prevent
clinic
diseas
analog
describ
pilu
antigen
first
describ
serolog
distinct
antigen
associ
e
coli
strain
isol
pig
edema
diseas
neonat
enter
later
demonstr
antigen
adher
factor
facilit
colon
small
intestin
confirm
sever
vivo
vitro
studi
wherein
adher
epec
intestin
villou
epithelium
block
antisera
antigen
base
find
vaccin
trial
carri
demonstr
sow
vaccin
epec
would
produc
high
level
colostr
antibodi
would
passiv
protect
newborn
suckl
pig
enter
diseas
produc
epec
numer
commerci
vaccin
avail
immun
sow
control
epecinduc
enter
offspr
describ
case
enter
colibacillosi
calv
due
epec
numer
epidemiolog
factor
contribut
develop
clinic
diseas
swine
herd
manag
confin
system
neonat
colibacillosi
unpredict
onset
sever
natur
analog
situat
calv
swine
herd
activ
immun
sow
carri
prior
outbreak
piglet
enter
morbid
mortal
might
reduc
passiv
immun
newborn
pig
direct
oral
administr
antibodi
p
l
sadowski
molecular
genet
inc
minnetonka
minnesota
person
commun
produc
monoclon
antibodi
use
techniqu
similar
describ
earlier
product
monoclon
antibodi
three
distinct
monoclon
antibodi
produc
show
specif
b
c
antigen
determin
antigen
protect
effect
c
antibodi
administ
oral
newborn
pig
demonstr
challeng
trial
use
epec
strain
interest
note
europ
activ
immun
sow
use
vaccin
contain
strain
epec
carri
number
year
epec
isol
obtain
intestin
pig
die
colibacillosi
field
outbreak
increasingli
varieti
less
frequent
varieti
appear
vaccin
exert
select
pressur
epec
organ
respond
variat
adher
structur
passiv
immun
piglet
monoclon
antibodi
could
also
potenti
contribut
select
pressur
altern
avid
monoclon
antibodi
might
capabl
block
adher
epec
despit
variat
secondari
structur
one
potenti
limit
passiv
immun
oral
administr
monoclon
antibodi
aris
fact
unlik
epec
infect
calf
restrict
first
day
life
epec
infect
pig
occur
throughout
suckl
wean
period
continu
administr
monoclon
antibodi
would
impract
passiv
immun
would
employ
face
outbreak
known
peak
period
suscept
name
first
day
life
wean
convent
diagnost
procedur
confirm
epec
infect
pig
similar
describ
epec
infect
sandwich
eli
describ
identif
pilu
bacteri
suspens
e
coli
cultur
clinic
specimen
reason
assum
monoclon
antibodi
facilit
develop
elisa
test
kit
allow
rapid
detect
antigen
directli
fecal
specimen
swab
c
pilu
pilu
also
restrict
porcin
isol
epec
often
associ
epec
strain
alway
found
heatstabl
enterotoxin
structur
glycoprotein
mw
rigid
fimbria
diamet
nm
unlik
hostspecif
adhesin
describ
demonstr
mannoseresist
hemagglutin
erythrocyt
code
bacteri
chromosom
rather
plasmid
role
adher
factor
facilit
colon
porcin
intestin
well
establish
purifi
pilu
fab
fragment
antibodi
specif
shown
block
adher
epec
strain
porcin
small
intestin
epitheli
cell
vitro
numer
challeng
trial
demonstr
antibodi
pilu
protect
piglet
enter
colibacillosi
epec
vaccin
sow
epec
increas
antibodi
level
colostrum
protect
suckl
pig
clinic
diseas
p
l
sadowski
molecular
genet
inc
minnetonka
minnesota
person
commun
produc
monoclon
antibodi
pilu
use
techniqu
similar
describ
product
monoclon
antibodi
protect
studi
carri
oral
administ
monoclon
antibodi
shown
protect
colostrumdepriv
newborn
piglet
challeng
epec
strain
signific
reduct
clinic
sever
diseas
mortal
rate
demonstr
compar
challeng
control
pig
receiv
monoclon
antibodi
outbreak
enter
colibacillosi
young
pig
may
due
either
strain
epec
although
tendenc
strain
produc
diarrhea
pig
week
age
strain
occur
frequent
younger
pig
much
overlap
infect
observ
suggest
prevent
enter
colibacillosi
piglet
oral
administr
monoclon
antibodi
specif
monoclon
antibodi
actual
handicap
practic
solut
problem
would
administr
trival
mixtur
monoclon
antibodi
three
known
porcin
epec
adher
pili
commerci
product
contain
monoclon
antibodi
adhesin
current
evalu
use
control
outbreak
enter
colibacillosi
young
pig
c
c
muscoplat
molecular
genet
inc
minnetonka
minnesota
person
commun
pilu
pilu
recent
character
adhesin
epec
import
veterinari
medicin
present
identifi
bovin
strain
epec
found
conjunct
pilu
certain
epec
strain
notabl
presenc
plasmid
mediat
occur
serogroup
epec
associ
exclus
heatstabl
enterotoxin
fimbrial
structur
diamet
nm
chemic
character
reveal
pilu
protein
mw
whose
amino
acid
sequenc
identifi
role
pilu
product
bovin
enter
colibacillosi
yet
firmli
establish
role
pilu
howev
sever
observ
suggest
pilu
virul
factor
mutant
strain
shown
adher
calf
enterocyt
vitro
produc
diarrhea
newborn
germfre
piglet
vaccin
trial
report
date
reason
assum
howev
role
clarifi
bovin
neonat
diarrhea
activ
immun
dam
produc
specif
colostr
antibodi
practic
turn
develop
monoclon
antibodi
direct
oral
passiv
immun
calf
like
follow
moraxella
bovi
infecti
bovin
keratoconjunct
ibk
common
cattl
diseas
major
econom
signific
comprehens
review
ibk
recent
publish
gener
accept
moraxella
bovi
primari
initi
mediat
diseas
although
role
numer
pathogen
includ
virus
mycoplasma
chlaymdia
suggest
infect
conjunctiva
bovi
produc
sever
inflamm
result
lacrim
blepharospasm
photophobia
corneal
edema
temporari
blind
residu
scar
ocular
pain
impair
vision
lead
reduc
feed
intak
decreas
milk
product
substanti
econom
loss
beef
dairi
cattl
produc
numer
factor
appear
contribut
initi
clinic
diseas
outbreak
ibk
occur
commonli
summer
autumn
attribut
increas
popul
face
fli
act
mechan
vector
bovi
season
increas
solar
radiat
predispos
cornea
infect
substanti
experiment
infect
control
exposur
ultraviolet
light
prior
challeng
bovi
increas
rate
sever
infect
lack
skin
pigment
eyelid
certain
cattl
breed
also
predispos
infect
corneal
irrit
dust
also
increas
suscept
multipl
predispos
factor
present
sever
outbreak
ibk
occur
suddenli
spread
rapidli
morbid
rate
report
high
although
bovi
link
ibk
sinc
consider
doubt
exist
concern
role
primari
pathogen
larg
due
difficulti
encount
consist
reproduc
experiment
infect
pedersen
et
al
demonstr
piliat
strain
bovi
capabl
colon
conjunctiva
calv
reproduc
diseas
presenc
pili
virul
strain
associ
distinct
flat
agarcorrod
coloni
morpholog
confirm
electron
microscopi
sinc
time
virtual
investig
pathogenesi
ibk
util
piliat
strain
bovi
discuss
advanc
diseas
control
base
manipul
immunolog
respons
host
pilu
pili
howev
recogn
virul
factor
bovi
report
product
hemolysin
also
characterist
strain
capabl
produc
ocular
diseas
role
sever
toxin
proteas
also
suggest
howev
enteropathogen
e
coli
pilu
major
import
prime
mediat
colon
colon
block
deleteri
effect
addit
virul
factor
may
minim
sever
line
investig
suggest
system
humor
immun
respons
may
prevent
infect
bovi
field
outbreak
ibk
young
cattl
suscept
adult
suggest
develop
natur
acquir
immun
pugh
et
al
demonstr
calv
receiv
colostrum
cow
vaccin
bovi
resist
experiment
challeng
calv
receiv
colostrum
unvaccin
dam
challeng
homolog
strain
also
demonstr
kopecki
et
al
calv
experiment
infect
one
eye
subsequ
develop
less
sever
clinic
diseas
challeng
eye
day
later
conclus
drawn
system
rather
local
immun
respons
respons
limit
diseas
sever
investig
measur
antibodi
respons
serum
lacrim
secret
infect
calv
killing
et
al
report
lacrim
secret
highest
persist
antibodi
titer
specif
bovi
igg
class
despit
fact
normal
calv
ig
predomin
antibodi
class
lacrim
secret
weech
renshaw
demonstr
bovisspecif
antibodi
lacrim
secret
direct
primarili
protein
antigen
includ
pilu
rather
carbohydr
antigen
investig
howev
unabl
detect
serum
antibodi
respons
infect
bishop
et
al
identifi
igg
respons
serum
challeng
calv
primarili
ig
respons
lacrim
secret
despit
somewhat
contradictori
find
investig
like
system
humor
immun
respons
import
defens
infect
bovi
appar
efficaci
parenter
vaccin
support
conclus
vaccin
formalinkil
aluminum
hydroxideadjuv
wholecel
bacterin
contain
two
highli
piliat
strain
bovi
experiment
challeng
trial
vaccin
given
subcutan
interv
produc
high
circul
antibodi
titer
pili
strain
measur
eli
substanti
reduc
rate
infect
vaccin
calv
compar
challeng
un
vaccin
control
vaccin
use
wide
field
appar
success
although
vaccin
abil
induc
protect
heterolog
field
strain
bovi
report
interestingli
littl
publish
data
exist
regard
character
bovi
pilu
term
chemic
physic
structur
genet
deriv
antigen
homolog
sinc
ibk
occur
worldwid
varieti
bovi
strain
isol
field
outbreak
differ
geograph
area
vaccin
failur
expect
occur
unless
vaccin
design
induc
strong
antibodi
respons
wide
share
pilu
antigen
identifio
common
epitop
consid
import
prerequisit
develop
efficaci
vaccin
current
investig
direct
toward
develop
pilu
vaccin
gonorrhea
instruct
schoolnik
et
al
examin
chemic
structur
antigen
divers
gonococc
pili
cyanogen
bromid
fragment
pili
differ
gonococc
strain
prepar
evalu
one
fragment
design
found
encompass
highli
conserv
antigen
region
mediat
receptor
cell
site
bind
function
immunorecess
fragment
identifi
immunodomin
includ
variabl
antigen
region
confer
type
specif
pilu
function
inert
virji
et
al
util
monoclon
antibodi
gonococc
pili
demonstr
common
antigen
region
typespecif
region
contain
one
epitop
report
pili
genera
neisseria
pseudomona
moraxella
show
homolog
ntermin
amino
acid
sequenc
suggest
protein
may
deriv
common
ancestr
gene
region
may
show
littl
structur
variat
necess
conserv
receptor
cell
site
bind
specif
success
colon
host
preliminari
work
g
k
schoolnik
stanford
univers
school
medicin
stanford
california
person
commun
begun
clarifi
pilu
structur
bovi
two
distinct
pili
identifi
bovi
strain
provision
design
heavi
light
molecular
weight
respect
amino
acid
sequenc
protein
determin
code
pili
chromosom
plasmid
mediat
dna
sequenc
code
light
pilu
defin
heavi
light
pili
share
common
antigen
region
approxim
amino
acid
nterminu
serologi
studi
show
antigen
region
immunorecess
remaind
pili
antigen
heterolog
variabl
region
immunodomin
sever
field
isol
bovi
also
demonstr
possess
pili
mw
identif
common
epitop
yet
carri
clearli
monoclon
antibodi
could
instrument
identifi
common
epitop
bovi
pili
furthermor
monoclon
antibodi
direct
common
pilu
epitop
might
use
effect
passiv
immun
unvaccin
cattl
risk
outbreak
ibk
immunologi
studi
host
respons
infect
cite
suggest
parenter
inject
pilusspecif
monoclon
antibodi
may
protect
colon
conjunctiva
serum
igg
appear
reach
lacrim
fluid
altern
monoclon
antibodi
could
instil
directli
eye
inject
subconjunctiv
space
current
done
antibiot
therpay
deliv
time
sustainedreleas
biodegrad
ocular
insert
recent
develop
passiv
immun
could
provid
veterinarian
great
flexibl
manag
ibk
particularli
situat
feedlot
cattl
assembl
multipl
sourc
may
develop
ibk
activ
immun
adequ
time
induc
protect
antibodi
respons
b
bacteroid
nodosu
infecti
foot
rot
sheep
inflamm
skin
horni
tissu
foot
infect
progress
soft
tissu
underneath
hoof
wall
sever
lame
occur
pain
impair
mobil
result
affect
pastur
sheep
lead
decreas
feed
intak
reduc
weight
gain
decreas
wool
product
increas
suscept
occasion
starvat
recogn
problem
nonarid
intens
sheepproduc
area
world
warm
temperatur
wet
weather
lush
pastur
import
trigger
clinic
diseas
sudden
outbreak
high
morbid
result
climat
condit
optim
bacteroid
nodosu
primari
etiolog
agent
infecti
foot
rot
sheep
oblig
parasit
hoof
epidermi
sheep
cattl
spread
clinic
outbreak
contamin
pastur
purul
discharg
infect
feet
pathogen
mechan
b
nodosu
clearli
defin
virul
strain
character
distinct
papil
beadedcoloni
morpholog
b
type
high
level
proteolyt
elastas
activ
abund
surfac
pili
wide
held
pilu
import
protect
immunogen
serv
basi
much
vaccin
research
howev
recent
report
antibodi
respons
natur
infect
sheep
suggest
pilu
may
predomin
immunogen
use
electroblot
radioimmunoassay
antibodi
respons
antigen
identifi
greatest
respons
direct
unidentifi
nonpilu
antigen
mw
compar
electron
microscop
studi
virul
nonvirul
strain
everi
skerman
confirm
presenc
abund
pili
virul
strain
also
identifi
presenc
addit
outer
membran
layer
aggreg
diffus
polar
materi
might
contribut
virul
begin
around
report
vaccin
efficaci
use
piliat
strain
b
nodosu
oil
adjuv
report
australia
new
zealand
england
protect
effect
observ
level
protect
roughli
correl
serum
pilu
antibodi
titer
virtual
studi
protect
demonstr
primarili
homolog
challeng
strain
howev
two
vaccin
trial
carri
unit
state
use
australianproduc
vaccin
demonstr
poor
protect
failur
prompt
investig
serotyp
heterogen
virul
field
strain
appear
pilu
k
antigen
b
nodosu
extrem
variabl
sever
studi
k
antigen
divers
report
number
identifi
serogroup
rang
australia
unit
state
use
pilu
antiserum
produc
rabbit
strong
agglutin
titer
homolog
pili
consist
produc
minor
crossreact
among
heterolog
pili
widespread
date
minor
crossreact
observ
agglutin
test
care
scrutin
conceiv
crossreact
repres
weak
immunologi
respons
common
epitop
b
nodosu
pili
epitop
immunorecess
situat
analog
describ
neisseria
gonorrhoea
possibl
moraxella
bovi
previous
discuss
clearli
hybridomaderiv
monoclon
antibodi
pilu
fragment
would
far
superior
convent
prepar
rabbit
antibodi
purpos
establish
exist
common
epitop
identif
common
immunogen
region
critic
develop
broadli
efficaci
pilu
vaccin
addit
specif
monoclon
antibodi
could
facilit
definit
immunogen
pathogen
role
b
nodosu
surfac
structur
implic
virul
factor
common
immunogen
defin
virul
strain
passiv
immun
parenter
inject
monoclon
antibodi
might
use
reduc
morbid
sporad
outbreak
infecti
foot
rot
un
vaccin
sheep
c
addit
pili
import
evidenc
discuss
attach
epitheli
cell
surfac
critic
first
step
pathogenesi
bacteri
infect
mucos
surfac
particularli
mechan
defens
peristalsi
ciliari
activ
resist
colon
recognit
fact
led
research
care
evalu
fimbrial
nonfimbri
adher
factor
mediat
infecti
diseas
human
veterinari
medicin
particularli
true
studi
respiratori
pathogen
respiratori
tract
diseas
continu
one
costliest
diseas
entiti
encount
veterinari
practic
signific
econom
loss
occur
cattl
swine
poultri
industri
due
respiratori
infect
trend
toward
confin
livestock
rear
industri
sector
exacerb
spread
respiratori
pathogen
studi
natur
bacteri
adher
respiratori
diseas
report
regard
pasteurella
multocida
bordetella
bronchiseptica
haemophilu
somnu
mycoplasma
pneumonia
infect
variou
speci
use
monoclon
antibodi
defin
mechan
structur
adher
respiratori
pathogen
nice
illustr
feldner
et
al
work
mycoplasma
pneumonia
human
respiratori
pathogen
studi
instruct
veterinari
research
known
pneumonia
small
size
possess
special
tip
structur
mobil
abil
adher
anim
cell
inert
surfac
adher
consid
prerequisit
surviv
host
organ
locat
structur
mycoplasm
adhesin
unknown
answer
question
mice
immun
wholecel
suspens
pneumonia
splenic
lymphocyt
harvest
hybridoma
produc
one
hundr
twenti
hybridoma
clone
screen
product
adherenceinhibit
antibodi
use
hemadsorpt
assay
limit
dilut
techniqu
singl
clone
isol
produc
desir
antibodi
util
monoclon
antibodi
indirectimmunofluoresc
test
whole
pneumonia
cell
local
area
fluoresc
identifi
one
pole
cell
electron
microscop
examin
use
ferritinlabel
antimous
monoclon
antibodi
confirm
monoclon
antibodi
bound
specif
unipolar
tip
structur
organ
fig
pretreat
pneumonia
cell
tipspecif
monoclon
antibodi
prevent
adher
sheep
rabbit
guinea
pig
human
erythrocyt
demonstr
adhes
abil
local
tip
structur
monoclon
antibodi
radiolabel
addit
methionin
hybridoma
cell
cultur
mycoplasma
pneumonia
cultur
solubil
sd
protein
separ
electrophoresi
sdspolyacrylamid
gel
gel
treat
label
monoclon
antibodi
autoradiographi
reveal
antibodi
bound
singl
protein
molecular
weight
rang
subsequ
coat
second
gel
sheep
erythrocyt
result
bind
red
cell
protein
indic
antigen
protein
function
bind
protein
ident
clearli
hybridoma
technolog
provid
power
investig
tool
defin
structur
function
bacteri
adhesin
use
monoclon
antibodi
studi
veterinari
respiratori
pathogen
undoubtedli
lead
greater
understand
hostparasit
interact
novel
approach
immunoprophylaxi
block
mechan
bacteri
adher
toxin
product
import
virul
mechan
particularli
noninvas
bacteria
abl
exert
profound
system
effect
host
despit
local
infect
clostridi
infect
classic
exampl
virul
mechan
human
medicin
hybridoma
technolog
appli
studi
bacteri
toxin
elucid
toxin
structur
pathogen
mechan
improv
immunodiagnost
capabl
develop
new
approach
immunotherapi
report
monoclon
antibodi
specif
bacteri
toxin
includ
studi
diphtheria
toxin
pseudomona
aeruginosa
exotoxin
clostridium
botulinum
toxin
c
clostridium
tetani
tetanu
toxin
illustr
potenti
use
toxinspecif
monoclon
antibodi
veterinari
medicin
sever
import
toxinmedi
diseas
discuss
discuss
earlier
enteropathogen
strain
e
coli
epec
possess
two
known
import
virul
factor
adher
pili
implement
intestin
colon
face
gut
peristalsi
compet
resid
intestin
flora
enterotoxin
stimul
intestin
epitheli
cell
secret
fluid
electrolyt
gut
lumen
acceler
rate
net
result
epec
infect
host
dehydr
acidosi
electrolyt
imbal
death
two
type
enterotoxin
recogn
epec
strain
isol
livestock
heatstabl
st
heatlabil
lt
enterotoxin
former
stimul
villou
cell
activ
guanyl
cyclas
epitheli
cell
latter
accomplish
task
activ
adenyl
cyclas
transmiss
enterotoxin
type
plasmid
mediat
epec
strain
associ
lt
st
enterotoxin
wherea
epec
found
produc
st
enterotoxin
although
valu
activ
immun
swine
cattl
piliat
vaccin
well
establish
passiv
immun
calv
monoclon
antibodi
demonstr
protect
enterotoxinspecif
monoclon
antibodi
could
play
import
futur
role
passiv
immun
neonat
observ
epec
isol
natur
infect
swine
less
frequent
type
frequent
type
suggest
pilu
plasmid
genom
respons
select
pressur
exert
vaccin
could
potenti
impair
longterm
efficaci
highli
specif
monoclon
antibodi
direct
variabl
region
pilu
enterotoxinspecif
monoclon
antibodi
offer
possibl
altern
continu
passiv
immun
combin
ltand
stspecif
antibodi
could
conceiv
neutral
enterotoxin
epec
strain
regardless
current
futur
pilu
specif
success
strategi
would
depend
inabl
enterotoxin
escap
immun
recognit
structur
variat
mediat
plasmid
genom
furthermor
colon
allow
occur
question
aris
whether
antibodi
success
bind
neutral
enterotoxin
physic
intim
associ
epec
organ
brush
border
epitheli
cell
facilit
adher
pili
may
present
spatial
constraint
limit
antibodyenterotoxin
interact
despit
theoret
concern
klipstein
et
al
shown
activ
immun
enterotoxin
reduc
intestin
use
vaccin
compos
synthet
produc
st
crosslink
nontox
b
subunit
lt
rat
rabbit
protect
challeng
toxin
heterolog
organ
produc
toxin
protect
measur
signific
decreas
intestin
use
ligat
gut
loop
assay
protect
effect
vaccin
attribut
mark
increas
toxinspecif
mucos
iga
gut
feasibl
produc
monoclon
antibodi
e
coli
enterotoxin
alreadi
demonstr
hemelhof
et
al
report
develop
monoclon
antibodi
heatstabl
enterotoxin
sth
human
epec
strain
monoclon
antibodi
dilut
exhibit
toxinneutr
potenc
time
greater
shown
convent
rais
antibodi
sth
interestingli
two
monoclon
antibodi
sth
report
neither
demonstr
abil
neutral
biolog
activ
enterotoxin
suggest
immunogen
region
exist
outsid
region
function
activ
structur
enterotoxin
pneumon
pasteurellosi
one
costliest
diseas
confront
cattl
industri
particularli
feedlot
sector
econom
consider
dictat
cattl
manag
practic
predispos
outbreak
respiratori
diseas
fibrin
pneumonia
due
pasteurella
haemolytica
consid
termin
event
multifactori
syndrom
known
bovin
respiratori
diseas
brd
complex
occur
high
frequenc
north
american
feedlot
stress
import
predispos
factor
develop
brd
feeder
calv
enter
feedlot
often
recent
wean
unadapt
grain
ration
comingl
strang
cattl
sale
barn
ship
long
distanc
inadequ
feed
water
subject
advers
weather
condit
comingl
cattl
multipl
sourc
lead
widespread
transmiss
respiratori
tract
virus
particularli
infecti
bovin
rhinotrach
viru
infect
virus
believ
predispos
cattl
develop
pasteurella
penumonia
presum
impair
pulmonari
clearanc
andor
immunosuppress
major
caus
mortal
brd
pneumon
pasteurellosi
feedlot
outbreak
brd
morbid
reach
mortal
addit
cattl
lost
treatment
cost
stagger
antibiot
therapi
costli
timeconsum
antibiot
resist
pasteurella
isol
increas
effort
reduc
morbid
tradit
includ
practic
vaccin
calv
viral
bacteri
pathogen
enter
feedlot
howev
mani
calv
may
alreadi
incub
respiratori
tract
virus
time
reach
feedlot
modifi
live
viru
vaccin
implic
ad
stressor
furthermor
pasteurella
bacterin
may
actual
contribut
sever
respiratori
diseas
discuss
later
fact
epidemiolog
studi
feedlot
mortal
canada
identifi
vaccin
cattl
upon
arriv
feedlot
one
three
import
factor
contribut
increas
mortal
rate
although
pasteurella
multocida
frequent
isol
outbreak
brd
p
haemolytica
consid
primari
bacteri
pathogen
twelv
rumin
serotyp
p
haemolytica
recogn
serotyp
often
isol
pneumon
lung
virul
factor
pathogen
mechan
p
haemolytica
complet
understood
viral
impair
pulmonari
clearanc
may
promot
increas
bacteri
entri
distal
lung
bacteri
surfac
adhesin
may
facilit
continu
colon
termin
bronchiol
alveoli
colon
cell
wall
endotoxin
releas
believ
initi
pulmon
lesion
develop
howev
attent
recent
focus
compound
releas
organ
pasteur
ella
haemolytica
found
produc
potent
cytotoxin
capabl
kill
polymorphonuclear
leukocyt
alveolar
macrophag
thu
disabl
primari
immunologi
defens
lung
bacteri
pathogen
physicochem
properti
cytotoxin
studi
himmel
et
al
purifi
partial
character
cytotoxin
protein
molecular
weight
approxim
associ
bacteri
capsul
protein
isol
cultur
supernat
shown
highli
immunogen
immunodiffus
test
antigen
crossreact
antisera
produc
serotyp
p
haemolytica
reactiv
demonstr
antisera
p
multocida
toxic
bovin
alveolar
macrophag
demonstr
vitro
shewen
wilki
also
report
similar
immunogen
cytotox
find
cytotoxin
cultur
supernat
univers
presenc
cytotoxin
serotyp
p
haemolytica
immunogen
probabl
role
import
virul
factor
make
cytotoxin
ideal
antigen
activ
immun
pneumon
pasteurellosi
examin
feedlot
cattl
submit
necropsi
diagnos
respiratori
diseas
lower
level
serum
anticytotox
neutral
antibodi
anim
die
caus
anim
bled
prior
entri
feedlot
immun
isol
cytotoxin
confer
protect
experiment
challeng
although
respons
surfac
antigen
appear
requir
complet
protect
may
analog
situat
epec
antibodi
pilu
toxin
may
give
best
respons
recognit
import
cytotoxin
help
explain
appar
neg
effect
vaccin
kill
wholecel
bacterin
sinc
cytotoxin
produc
abundantli
logphas
growth
cultur
convent
prepar
bacterin
contain
bacteria
stationaryphas
growth
induc
much
anticapsular
opson
antibodi
may
produc
littl
cytotoxinneutr
antibodi
lead
increas
phagocyt
activ
also
may
result
effici
kill
phagocyt
cytotoxin
releas
ingest
bacteria
net
effect
vaccin
may
impair
immun
respons
although
redesign
bacterin
promot
better
anticytotoxin
respons
would
result
better
vaccin
ensur
develop
better
vaccin
program
fact
realiti
feedlot
practic
argu
valu
activ
immun
techniqu
control
brd
outbreak
brd
occur
within
day
arriv
feedlot
environment
stress
calf
greatest
yet
cattl
vaccin
upon
arriv
expect
develop
strong
humor
immun
respons
within
first
week
endogen
steroid
releas
due
stress
concurr
viral
infect
may
impair
anim
abil
mount
effect
immun
respons
even
best
vaccin
ideal
calv
vaccin
market
feedlot
precondit
howev
calf
raiser
gener
unwil
incur
expens
vaccin
protect
futur
econom
interest
prospect
feedlot
calf
buyer
clearli
passiv
immun
could
play
import
role
control
brd
fit
logic
epidemiolog
pattern
feedlot
diseas
feedlot
manag
practic
antibodi
administ
parenter
cattl
upon
arriv
feedlot
could
protect
clinic
diseas
critic
adapt
period
hybridoma
technolog
offer
signific
advantag
convent
prepar
antisera
passiv
immun
allow
product
unlimit
quantiti
hightit
antibodi
direct
specif
virul
factor
monoclon
antibodi
cytotoxin
administ
alon
conjunct
monoclon
antibodi
antigen
p
haemolytica
protein
known
respiratori
viral
pathogen
could
dramat
improv
current
approach
control
respiratori
diseas
cattl
wide
rang
clostridi
diseas
affect
farm
anim
includ
tetanu
cl
tetani
botul
cl
botulinum
blackleg
cl
chauvoei
malign
edema
cl
septicum
cl
novyi
necrot
hepat
cl
novyi
bacillari
hemoglobinuria
cl
haemolyticwn
enterotoxemia
cl
perfringen
diseas
mediat
releas
potent
clostridi
toxin
gener
diseas
effect
control
vaccin
alumprecipit
toxoid
howev
seriou
outbreak
continu
occur
unvaccin
anim
success
therapi
depend
administr
larg
dose
specif
antitoxin
commerci
avail
convent
prepar
antitoxin
vari
consider
cost
avail
efficaci
seriou
limit
treatment
rel
high
cost
administ
adequ
dose
antitoxin
exampl
recommend
treatment
regimen
adult
hors
tetanu
unit
tetanu
antitoxin
administ
three
time
interv
current
cost
therapi
approxim
demonstr
antibodi
clostridi
toxin
prepar
use
hybridoma
technolog
oguma
et
al
report
product
four
differ
monoclon
antibodi
c
toxin
cl
botulinum
one
show
neutral
activ
biolog
activ
toxin
suggest
convent
prepar
antitoxin
signific
proport
antibodi
produc
may
possess
neutral
activ
volk
et
al
produc
number
mous
monoclon
antibodi
tetanu
toxoid
antibodi
bound
least
differ
epitop
toxoid
molecul
mixtur
antibodi
demonstr
greater
neutral
activ
alon
suggest
effici
neutral
requir
antibodi
bind
one
site
toxoid
molecul
compar
high
titer
hybridomaderiv
antibodi
along
potenti
improv
specif
could
significantli
improv
efficaci
antitoxin
therapi
monoclon
antibodi
use
instead
convent
prepar
antitoxin
hybridoma
technolog
could
conceiv
result
lower
cost
product
higher
potenc
therapeut
use
paratuberculosi
john
diseas
chronic
granulomat
enter
infect
rumin
anim
caus
acidfast
organ
mycobaeterium
paratuberculosi
diseas
occur
worldwid
consid
major
problem
north
american
cattl
industri
infect
herd
clinic
ill
anim
diarrhea
shed
organ
fece
paratuberculosi
infect
confirm
bacteri
cultur
techniqu
also
true
percentag
infect
anim
show
clinic
sign
howev
mani
infect
anim
herd
nonshed
carrier
identifi
cultur
fece
effort
elimin
john
diseas
frustrat
decad
lack
sensit
specif
immunodiagnost
test
identif
nonshed
carrier
anim
wide
rang
diagnost
test
evalu
detect
humor
cellular
immun
respons
infect
effort
review
virtual
case
diagnost
specif
inadequ
result
antigen
crossreact
mycobaeterium
paratuberculosi
share
common
cell
wall
antigen
varieti
pathogen
saprophyt
bacteria
includ
mycobacteria
sp
corynebacterium
sp
nocardia
sp
histor
difficulti
led
renew
emphasi
isol
typespecif
antigen
protoplasm
extract
paratuberculosi
util
newer
sensit
diagnost
assay
eli
abba
et
al
report
isol
affinitypurifi
peptid
deriv
crude
protoplasm
extract
paratuberculosi
crude
extract
obtain
disrupt
whole
cell
ribi
hydraul
cell
press
separ
cell
wall
debri
centrifug
lyophil
remain
supernat
isol
peptid
antigen
involv
complic
stepwis
procedur
crude
protoplasm
extract
treat
solvent
extract
ammonium
sulfat
precipit
follow
gel
filtrat
ion
exchang
chromatographi
final
affin
chromatographi
yield
peptid
antigen
crude
materi
appli
affin
column
wherea
crude
start
materi
demonstr
crossreact
bovin
antisera
avium
phlei
fortuitum
nocardia
complement
fixat
eli
test
purifi
peptid
react
antisera
paratuberculosi
complement
fixat
elisa
antisera
dilut
although
purif
antigen
applic
elisa
system
repres
major
advanc
immunodiagnosi
paratuberculosi
applic
hybridoma
technolog
could
elimin
need
exhaust
purif
protoplasm
antigen
hewitt
et
al
report
use
monoclon
antibodi
serodiagnosi
human
tuberculosi
without
need
purif
antigen
assay
describ
competitiveinhibit
assay
wherein
crude
tuberculosi
antigen
pressat
bound
microtit
plate
well
test
sera
incub
coat
well
follow
addit
ilabel
murin
monoclon
antibodi
direct
typespecif
antigen
tuberculosi
plate
wash
amount
bound
monoclon
antibodi
determin
count
indirect
measur
tuberculosisspecif
antibodi
test
sera
combin
differ
antigenspecif
monoclon
antibodi
employ
assay
improv
sensit
emphas
mycobacteri
infect
present
wide
rang
antigen
host
may
recogn
ignor
variabl
degre
host
immun
respons
therefor
sensit
immunoassay
improv
util
monoclon
antibodi
sever
known
typespecif
antigen
preval
host
recognit
peptid
antigen
paratuberculosi
describ
abba
et
al
current
unknown
although
report
studi
sera
known
infect
anim
test
identifi
posit
elisa
assay
antigen
could
use
produc
mous
monoclon
antibodi
use
competitiveinhibit
assay
describ
crude
protoplasm
extract
paratuberculosi
serv
test
antigen
addit
monoclon
antibodi
could
use
probe
identifi
protoplasm
antigen
paratuberculosi
crossreact
could
therefor
use
improv
sensit
competitiveinhibit
test
morri
ivanyi
recent
report
pattern
cross
reactiv
protoplasm
antigen
variou
mycobacteria
includ
paratuberculosi
panel
ten
monoclon
antibodi
produc
tuberculosi
lepra
antigen
radioimmunoassay
employ
detect
bind
activ
bacteri
capsul
play
import
role
pathogenesi
bacteri
infect
larg
abil
inhibit
phagocytosi
two
gener
mechan
antiphagocyt
activ
recogn
first
abund
capsul
may
cover
cell
surfac
antigen
pili
cell
wall
lipopolysaccharid
lp
prevent
phagocyt
interact
subcapsular
determin
second
polysaccharid
capsul
fix
complement
absenc
antibodi
thu
inhibit
complementmedi
opson
polysaccharid
capsul
mani
bacteria
highli
immunogen
howev
immun
capsulerich
vaccin
promot
anticapsular
antibodi
product
capabl
mediat
complement
fixat
phagocytosi
human
medicin
excit
approach
immunotherapi
explor
use
monoclon
antibodi
capsular
antigen
group
b
streptococcu
bacteria
respons
potenti
fatal
septicemia
newborn
infant
sinc
infect
occur
passag
birth
canal
occurr
unpredict
activ
immun
repres
practic
approach
manag
problem
situat
analog
mani
veterinari
diseas
alreadi
discuss
shigeoka
et
al
report
develop
murin
monoclon
antibodi
igm
class
prepar
group
b
streptococc
gb
type
iii
polysaccharid
antigen
one
monoclon
antibodi
use
rat
model
infect
significantli
reduc
mortal
rat
challeng
five
differ
gb
type
iii
strain
two
strain
normal
resist
opson
human
sera
contain
opson
antibodi
mortal
rat
significantli
reduc
even
monoclon
antibodi
administ
late
hr
challeng
suggest
antibodi
could
use
immunotherapi
well
immunoprophi
iaxi
similar
protect
effect
shown
monoclon
antibodi
capsular
antigen
haemophilu
influenza
veterinari
medicin
role
capsul
well
defin
mani
bacteri
pathogen
capsular
antigen
occur
wide
among
enterobacteriacaea
propos
play
role
adher
enteropathogen
e
coli
addit
aforement
pili
capsular
k
antigen
also
involv
pathogenesi
e
coli
infect
among
gramposit
organ
staphylococcu
aureu
import
mastiti
pathogen
possess
numer
mechan
escap
phagocytosi
among
capsul
two
streptococci
equi
group
e
streptococcu
swine
recogn
antiphagocyt
properti
howev
due
possess
cell
wallassoci
protein
rather
polysaccharid
capsul
present
diagnost
therapeut
prophylact
applic
monoclon
antibodi
capsular
antigen
veterinari
pathogen
remain
larg
unexplor
hybridoma
technolog
contribut
better
understand
structur
function
import
capsular
antigen
turn
may
lead
clearer
idea
clinic
applic
monoclon
antibodi
cell
wall
structur
receiv
great
deal
attent
immunogen
virul
factor
cell
wall
lp
gramneg
bacteria
strongli
antigen
serv
basi
taxonom
classif
gramneg
organ
lipid
moieti
gramneg
bacteri
lp
identifi
potent
compon
endotoxin
molecul
exert
power
welldefin
toxic
effect
infect
host
waxi
cell
wall
acidfast
organ
mycobacteria
instrument
facilit
intracellular
surviv
phagocyt
bacteria
lead
chronic
granulomat
infect
peptidoglycan
compon
gramposit
bacteri
cell
wall
also
demonstr
produc
endotoxinlik
activ
adjuv
activ
addit
gramposit
organ
possess
cell
wallrel
protein
protein
staphylococcu
aureu
protein
group
streptococci
assist
organ
avoid
phagocytosi
establish
infect
section
three
potenti
applic
monoclon
antibodi
cell
wall
compon
veterinari
pathogen
discuss
brucellosi
due
brucella
abortu
import
zoonot
diseas
rumin
anim
caus
undul
fever
human
unit
state
feder
regulatori
diseas
control
program
establish
significantli
reduc
elimin
brucellosi
cattl
essenti
element
control
program
restrict
cattl
movement
identif
destruct
infect
anim
vaccin
calv
live
avirul
b
abortu
strain
vaccin
vaccin
import
compon
program
howev
product
antibodi
vaccin
anim
well
occurr
organ
induc
crossreact
antibodi
confound
accur
diagnosi
natur
occur
brucellosi
infect
recogn
seriou
obstacl
total
elimin
brucellosi
nation
herd
numer
approach
improv
strain
specif
test
explor
hybridoma
technolog
offer
promis
solut
longstand
problem
identif
strain
cell
wall
antigen
well
typespecif
antigen
yersinia
enterocolitica
common
crossreact
organ
might
expedit
use
monoclon
antibodi
probe
monoclon
antibodi
develop
strainspecif
antigen
could
use
competit
assay
competitiveinhibit
assay
describ
earlier
diagnosi
tuberculosi
discrimin
natur
b
abortu
infect
strain
vaccin
spontan
infect
crossreact
organ
sever
report
develop
monoclon
antibodi
cell
wall
lp
antigen
bruceila
strain
applic
alreadi
appear
first
work
schurig
illustr
use
monoclon
antibodi
brucella
competit
elisa
test
discrimin
antibodi
e
coli
lp
antigen
antibodi
brucella
lp
antigen
sera
immun
anim
anoth
studi
monoclon
antibodi
specif
chain
polysaccharid
yersinia
enterocolitica
found
agglutin
sever
biotyp
b
abortu
conclud
antigen
b
abortu
ident
chain
polysaccharid
enterocolitica
streptococcu
equi
caus
sever
lymphadenopathi
hors
result
abscess
ruptur
lymph
node
primarili
head
neck
region
condit
commonli
known
strangl
due
sever
respiratori
impair
result
swell
pharyng
lymph
node
certain
manag
situat
equi
infect
reach
epidem
proport
particularli
true
breed
farm
train
stabl
continu
turnov
larg
number
hors
contamin
environ
purul
materi
drain
abscess
promot
spread
diseas
facil
strangl
becom
endem
problem
young
foal
accompani
mare
breed
farm
particularli
suscept
commerci
bacterin
avail
vaccin
equi
degre
protect
afford
immun
variabl
vaccin
suscept
foal
introduc
onto
contamin
premis
littl
valu
repres
anoth
situat
veterinari
medicin
effect
product
passiv
immun
popul
risk
would
help
control
diseas
numer
equi
antigen
examin
potenti
protect
immunogen
includ
peptidoglycan
mureinteicho
acid
complex
group
c
carbohydr
lancefield
extract
protein
cell
wall
protein
similar
protein
group
streptococci
mlike
protein
first
character
woolcock
particular
interest
shown
potent
immunogen
produc
high
antibodi
titer
hors
rabbit
srivastava
barnum
report
vaccin
poni
foal
purifi
alumprecipit
mlike
protein
protect
infect
via
contact
exposur
hors
activ
strangl
antibodi
level
produc
vaccin
mlike
protein
equival
level
occur
natur
infect
equi
find
suggest
monoclon
antibodi
direct
mlike
protein
could
use
passiv
immun
foal
equi
infect
although
time
unclear
whether
circul
serum
antibodi
alon
afford
adequ
protect
diseas
evid
exist
cellular
immun
respons
well
local
mucos
immun
respons
nasopharynx
play
role
host
protect
nevertheless
valu
passiv
immun
parenter
administ
monoclon
antibodi
merit
futur
evalu
one
excit
potenti
applic
hybridoma
technolog
veterinari
human
medicin
develop
monoclon
antibodi
common
core
lp
fraction
endotoxin
use
immunotherapi
immunoprophylaxi
broad
rang
gramneg
pathogen
involv
wide
varieti
specif
diseas
entiti
possibl
even
theoriz
credit
mani
basic
clinic
research
care
studi
structur
function
clinic
effect
gramneg
endotoxin
variat
antigen
gramneg
bacteria
result
divers
structur
oligosaccharid
side
chain
cell
wall
lp
although
antigen
highli
immunogen
structur
divers
lead
serolog
distinct
antibodi
respons
littl
crossreact
occur
heterolog
strain
given
stagger
number
gramneg
bacteri
speci
strain
capabl
produc
seriou
infect
activ
immun
never
receiv
seriou
consider
mean
effect
control
gramneg
infect
howev
recognit
problem
antigen
divers
prompt
investig
identif
share
cell
wall
antigen
might
serv
common
immunogen
crossprotect
vaccin
mccabe
et
al
review
background
develop
area
research
major
advanc
describ
briefli
summar
et
al
report
structur
similar
core
portion
gramneg
cell
wall
lp
salmonella
sp
relat
enterobacteriacea
observ
despit
variat
termin
oligosaccharid
structur
confer
antigen
speci
examin
possess
common
core
antigen
compos
lipid
attach
ketodeoxyocton
kdo
heptos
core
structur
immunogen
mutant
strain
typhimurium
minnesota
e
coli
identifi
fail
synthes
oligosaccharid
side
chain
cell
wall
lp
two
stabl
mutant
mutant
minnesota
mutant
e
coli
use
number
immun
studi
demonstr
antibodi
produc
core
lp
determin
significantli
protect
laboratori
anim
challeng
infect
broad
rang
gramneg
organ
includ
salmonella
e
coli
speci
klebsiella
sp
pseudomona
sp
haemophilu
influenza
encourag
find
led
investig
role
core
lp
antibodi
protect
human
patient
effect
gramneg
septicemia
mccabe
et
al
measur
natur
occur
antibodi
core
lp
determin
well
antibodi
typespecif
antigen
human
patient
gramneg
septicemia
mark
correl
observ
antibodi
titer
core
lp
sever
clinic
diseas
patient
high
antibodi
titer
core
lp
measur
indirect
hemagglutin
far
less
like
develop
shock
die
patient
low
antibodi
titer
core
lp
phenomenon
appear
independ
antibodi
titer
typespecif
antigen
infect
organ
ziegler
et
al
immun
human
volunt
mutant
e
coli
b
produc
human
antiserum
core
lp
administ
hospit
patient
gramneg
septicemia
doubleblind
clinic
trial
mortal
significantli
reduc
patient
receiv
antiserum
comparison
patient
receiv
nonimmun
serum
even
among
patient
experienc
profound
shock
patient
infect
broad
rang
unrel
gramneg
organ
mutharia
et
al
recent
produc
four
monoclon
antibodi
mutant
e
coli
react
purifi
lp
e
coli
mutant
minnesota
agrobacterium
tumefacien
pseudomona
aeruginosa
addit
purifi
lipid
p
aeruginosa
antibodi
also
react
elisa
outer
membran
prepar
strain
variou
gramneg
bacteria
show
reactiv
gramposit
speci
result
add
credenc
concept
widespread
conserv
singl
antigen
site
lipid
divers
gramneg
bacteria
illustr
power
monoclon
antibodi
investig
tool
recent
report
shown
cross
reactiv
monoclon
antibodi
e
coli
endotoxin
even
greater
antibodi
react
whole
heterolog
organ
rather
purifi
lp
extract
find
rais
hope
vaccin
contain
core
lp
determin
develop
immun
divers
gramneg
bacteri
infect
addit
antibodi
core
lp
could
use
passiv
immun
patient
risk
burn
patient
immunocompromis
patient
chemotherapi
well
immunotherapi
earli
stage
gramneg
bacteri
septicemia
monoclon
antibodi
deriv
hybridoma
technolog
would
logic
method
produc
therapeut
prophylact
antibodi
obviat
problem
rais
convent
antisera
human
be
would
yield
specif
antibodi
much
higher
concentr
concentr
antibodi
administ
therapeut
purpos
probabl
critic
factor
overwhelm
gramneg
sepsi
antibodi
rapidli
consum
potenti
applic
monoclon
antibodi
core
lp
veterinari
medicin
numer
econom
benefit
deriv
passiv
immun
immunotherapi
enorm
mani
costli
clinic
syndrom
livestock
known
thought
involv
gramneg
bacteri
septicemia
endotoxemia
includ
among
other
colisepticemia
newborn
calv
shigellosi
foal
agalactia
sow
salmonellosi
cattl
hors
postop
endotoxemia
hors
coliform
mastiti
cattl
mani
condit
character
high
mortal
rate
even
face
aggress
antibiot
therapi
support
care
abil
interven
condit
monoclon
antibodi
core
lp
would
incalcul
benefit
clinic
veterinari
medicin
three
main
area
applic
monoclon
antibodi
bacteri
antigen
veterinari
medicin
discuss
name
passiv
immun
improv
immunodiagnost
immunotherapi
although
mani
propos
applic
present
chapter
specul
author
attempt
limit
discuss
bacteri
diseas
exist
knowledg
antigen
structur
virul
mechan
host
respons
infect
suffici
make
specul
realist
whenev
possibl
potenti
applic
support
discuss
analog
develop
human
medic
research
lend
credenc
specul
veterinari
medicin
addit
research
involv
specif
veterinari
pathogen
determin
whether
potenti
applic
hypothes
success
implement
practic
hope
chapter
encourag
veterinari
research
examin
critic
propos
applic
monoclon
antibodi
undoubtedli
mani
addit
practic
applic
hybridoma
technolog
veterinari
medicin
elud
imagin
interest
reader
like
develop
addit
idea
occur
chapter
serv
use
purpos
passiv
immun
use
monoclon
antibodi
may
dramat
alter
tradit
approach
diseas
control
veterinari
medicin
sever
aspect
veterinari
livestock
practic
underscor
need
effect
passiv
immun
agent
livestock
produc
resist
idea
activ
immun
infecti
diseas
even
efficaci
vaccin
avail
much
resist
due
econom
realiti
livestock
product
profit
margin
narrow
cost
vaccin
weigh
risk
experienc
diseas
outbreak
unfortun
mani
case
risk
weigh
incorrectli
veterinarian
call
halt
rapid
spread
infecti
diseas
highli
suscept
popul
livestock
valu
passiv
immun
situat
unquestion
evidenc
appar
success
monoclon
antibodi
control
outbreak
fatal
diarrhea
neonat
calv
due
enteropathogen
e
coli
situat
risk
diseas
recogn
high
activ
immun
carri
manag
factor
preclud
valu
vaccin
particularli
true
feedlot
suscept
popul
cattl
access
vaccin
prior
period
highest
diseas
risk
infect
establish
protect
antibodi
produc
host
passiv
immun
repres
logic
immunologi
defens
monoclon
antibodi
specif
unlimit
avail
high
titer
repres
excel
passiv
immun
agent
howev
potenti
use
prevent
infect
must
evalu
casebycas
basi
host
natur
respond
infect
local
mucos
immun
respons
cellular
immun
respons
parenter
administr
monoclon
antibodi
may
provid
adequ
protect
infect
local
infect
mucos
surfac
monoclon
antibodi
may
need
administ
specif
site
circul
antibodi
particip
immunologi
control
infect
wherea
easili
accomplish
enter
colibacillosi
oral
administr
monoclon
antibodi
logist
administ
monoclon
antibodi
termin
airway
respiratori
diseas
mechan
complex
select
appropri
antibodi
class
may
also
import
depend
whether
opson
bacteria
depend
complement
activ
appear
work
antibodi
core
lp
endotoxin
antibodi
igm
class
protect
igg
antibodi
situat
bacteria
capabl
produc
proteas
degrad
secretori
iga
monoclon
antibodi
class
might
effect
halfliv
either
heterolog
homolog
monoclon
antibodi
must
also
taken
account
especi
passiv
immun
longterm
therapi
anticip
perhap
signific
limit
widespread
applic
monoclon
antibodi
passiv
immun
current
depend
hybridoma
technolog
murin
cell
line
repeat
applic
murinederiv
monoclon
antibodi
livestock
speci
undoubtedli
lead
develop
host
antimurin
antibodi
would
destroy
immunologi
activ
administ
monoclon
antibodi
perhap
induc
allerg
sensit
problem
requir
develop
new
cell
line
capabl
produc
speciesspecif
antibodi
recent
report
success
humanmurin
bovinemurin
porcinemurin
fusion
capabl
produc
human
bovin
porcin
immunoglobulin
respect
offer
much
hope
futur
area
immunodiagnost
monoclon
antibodi
particular
valu
veterinari
medicin
result
specif
monoclon
antibodi
ideal
suit
identifi
specif
antigen
crude
antigen
mixtur
unpurifi
specimen
illustr
develop
eli
test
kit
use
monoclon
antibodi
detect
antigen
directli
fecal
sampl
veterinarian
livestock
practic
work
independ
rel
isol
develop
test
kit
field
use
dramat
reduc
depend
central
diagnost
laboratori
increas
avail
test
result
addit
monoclon
antibodi
undoubtedli
lead
refin
current
method
serodiagnosi
particularli
case
antigen
crossreact
lead
decreas
specif
paratuberculosi
brucellosi
prime
exampl
immunotherapi
becom
increasingli
popular
human
medicin
mani
potenti
applic
exist
veterinari
medicin
well
immunotherapi
particularli
attract
veterinari
medicin
altern
antibiot
therapi
use
antibiot
livestock
strictli
regul
select
antibiot
practition
often
depend
much
persist
meat
milk
egg
suscept
infect
organ
exampl
use
aminoglycosid
antibiot
cattl
requir
withhold
period
treat
cattl
market
meat
inhibit
use
aminoglycosid
even
therapeut
use
indic
even
importantli
societ
awar
concern
adulter
food
suppli
potenti
transfer
drug
resist
anim
pathogen
human
pathogen
demand
profess
veterinari
medicin
identifi
implement
effect
altern
antibiot
use
immunotherapi
monoclon
antibodi
repres
one
like
altern
new
research
activ
direct
toward
develop
broad
rang
immunotherapeut
agent
use
hybridoma
technolog
although
scope
chapter
limit
applic
monoclon
antibodi
bacteria
veterinari
medicin
equal
excit
develop
occur
area
veterinari
virolog
mycolog
parasitolog
neoplast
diseas
doubt
hybridoma
technolog
acceler
pace
basic
research
veterinari
medicin
lead
broad
rang
diagnost
clinic
applic
chang
face
veterinari
practic
year
come
current
futur
applic
monoclon
antibodi
bacteria
veterinari
medicin
discuss
aspect
veterinari
practic
make
develop
hybridoma
technolog
particularli
attract
veterinari
medicin
emphas
exist
applic
monoclon
antibodi
detail
includ
use
pilusspecif
monoclon
antibodi
passiv
immun
calv
piglet
enteropathogen
e
coli
epec
infect
well
develop
rapid
diagnost
test
kit
field
diagnosi
epec
infect
potenti
applic
monoclon
antibodi
passiv
immun
varieti
veterinari
pathogen
present
includ
passiv
immun
moraxella
bovi
pinkey
bacteroid
nodosu
foot
rot
epec
enterotoxin
enter
colibacillosi
pasteurella
haemolytica
pneumon
pasteurellosi
streptococcu
equi
strangl
potenti
diagnost
applic
import
veterinari
pathogen
discuss
includ
diagnosi
mycobacterium
paratuberculosi
infect
john
diseas
bruceila
abortu
brucellosi
potenti
applic
immunotherapi
use
monoclon
antibodi
also
discuss
includ
therapi
clostridi
infect
use
monoclon
antibodi
clostridi
toxin
gramneg
bacteri
infect
use
monoclon
antibodi
common
core
lipopolysaccharid
determin
gramneg
cell
wall
endotoxin
conclus
present
concern
role
hybridoma
technolog
futur
progress
veterinari
medicin
